menu search

PSTV / Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial

Biocept enters into comprehensive laboratory services agreement with Plus Therapeutics for cancer trial
Biocept Inc (NASDAQ:BIOC) and Plus Therapeutics Inc have announced a comprehensive laboratory services agreement for Plus Therapeutics' ReSPECT-LM trial for the treatment of cancer in the membranes that surround the brain and spinal cord.  Under the multi-year agreement, Biocept's cerebrospinal fluid (CSF) assay CNSide1 will be employed in Plus Therapeutics' ReSPECT-LM Phase 1/2a dose-escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of patients with leptomeningeal metastases (LM). Read More
Posted: Jun 22 2022, 09:11
Author Name: Proactive Investors
Views: 102542

PSTV News  

Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

By Seeking Alpha
October 31, 2023

Plus Therapeutics, Inc. (PSTV) Q3 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q3 2023 Earnings Conference Call October 31, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President an more_horizontal

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

By GlobeNewsWire
September 11, 2023

Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical compa more_horizontal

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 14, 2023

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and more_horizontal

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

By GlobeNewsWire
August 8, 2023

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

By GlobeNewsWire
August 3, 2023

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

By GlobeNewsWire
May 25, 2023

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company more_horizontal

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

By Seeking Alpha
April 20, 2023

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript. more_horizontal

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
April 20, 2023

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 p more_horizontal


Search within

Pages Search Results: